公开(公告)号：EP3405195A1

公开(公告)日：2018-11-28

申请号：EP17703665.4

申请日：2017-01-20

申请人： STADA Arzneimittel AG

发明人： SCHÖNBORN, Jessica

IPC分类号： A61K31/4545 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K31/4545 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077

摘要： The invention relates to a method for producing a pharmaceutical granulate containing apixaban or a salt thereof as an ingredient. The aim of the invention is to provide a method in which the ingredient can be used largely independently of the particle size distribution of the ingredient, but dosage forms exhibiting sufficiently consistent ingredient dissolution rates for an undelayed ingredient release can still be produced using the resulting granulate, however. This is achieved by a method of the generic type having the following steps: a) providing a solvent; b) combining the solvent with the ingredient, thereby obtaining a granulation liquid; and c) wet-granulating a powder material using the granulating liquid.

公开(公告)号：EP2285410B1

公开(公告)日：2018-09-26

申请号：EP09728065.5

申请日：2009-04-02

申请人： Boehringer Ingelheim International GmbH

发明人： FRIEDL, Thomas ,  BRAUN, Michael ,  EGUSA, Kenji ,  FUJITA, Hikaru ,  MARUYAMA, Megumi ,  NISHIOKA, Takaaki

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K31/155 ,  A61K31/522 ,  A61K9/24 ,  A61K45/06 ,  A61K47/18 ,  A61P3/10

CPC分类号： A61K31/522 ,  A61K9/0053 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/28 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2866 ,  A61K31/155 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

公开(公告)号：EP2925304B1

公开(公告)日：2018-09-05

申请号：EP13859441.1

申请日：2013-11-27

申请人： Acura Pharmaceuticals, Inc.

发明人： BRZECZKO, Albert, W. ,  HOLLENBECK, R., Gary

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/48

CPC分类号： A61K47/02 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2077 ,  A61K31/5517 ,  A61K47/32

摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

公开(公告)号：EP2555756B1

公开(公告)日：2018-08-22

申请号：EP11711632.7

申请日：2011-02-07

申请人： Lupin Limited

发明人： DESHMUKH, Ashish, Ashokrao ,  BHUTADA, Pravin, Meghrajji ,  CHANDRAN, Sajeev ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/20 ,  A61K9/16 ,  A61K9/50 ,  A61K45/06 ,  A61K31/137

CPC分类号： A61K9/209 ,  A61K9/0004 ,  A61K9/0065 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/137 ,  A61K45/06 ,  A61K2300/00

摘要： A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.

公开(公告)号：EP1986616B1

公开(公告)日：2018-08-15

申请号：EP07712232.3

申请日：2007-02-16

申请人： Flamel Ireland Limited

发明人： GUIMBERTEAU, Florence ,  DARGELAS, Frédéric

IPC分类号： A61K9/48 ,  A61K9/50 ,  A61K9/16 ,  A61K9/52 ,  A61K9/32 ,  A61K9/26

CPC分类号： A61K9/1676 ,  A61K9/0095 ,  A61K9/1652 ,  A61K9/2077 ,  A61K9/2866 ,  A61K9/4816 ,  A61K9/4891 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5078 ,  A61K9/5084

公开(公告)号：EP3344240A1

公开(公告)日：2018-07-11

申请号：EP16842482.8

申请日：2016-07-07

申请人： Wellesley Pharmaceuticals, LLC

发明人： DILL, David, A.

IPC分类号： A61K31/167 ,  A61K31/618 ,  A61K31/192

CPC分类号： A61K31/192 ,  A61K9/167 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/282 ,  A61K9/2893 ,  A61K31/12 ,  A61K31/167 ,  A61K31/19 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/405 ,  A61K31/46 ,  A61K31/4725 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

摘要： Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

公开(公告)号：EP3220916A4

公开(公告)日：2018-07-11

申请号：EP15860676

申请日：2015-11-17

申请人： EPIZYME INC ,  EISAI R&D MAN CO LTD

发明人： KEILHACK HEIKE ,  TRUITT BRETT ,  SUZUKI YUTA ,  MURASE TSUKASA ,  SHIKATA FUTOSHI

IPC分类号： A61K31/5377 ,  A61K9/20 ,  A61P35/00

CPC分类号： A61K31/5377 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/2846 ,  A61K9/2893

摘要： The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).

公开(公告)号：EP3287124A1

公开(公告)日：2018-02-28

申请号：EP17186636.1

申请日：2015-04-16

申请人： Develco Pharma Schweiz AG

发明人： MANTHEI, Sascha ,  REY, Helene ,  FISCHER, Marc ,  MUNDSZINGER, Olaf

IPC分类号： A61K9/20 ,  A61K31/135 ,  A61K9/00 ,  A61K9/50

CPC分类号： A61K31/135 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078

摘要： The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.

公开(公告)号：EP3285745A1

公开(公告)日：2018-02-28

申请号：EP16719366

申请日：2016-04-22

申请人： GRÜNENTHAL GMBH

发明人： WENING KLAUS ,  GEISSLER ANJA ,  DENKER JANA ,  BARNSCHEID LUTZ

IPC分类号： A61K9/16 ,  A61K31/485

CPC分类号： A61K31/485 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/1694 ,  A61K9/2077 ,  A61K9/4808 ,  A61K9/50 ,  A61K31/137

摘要： A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.

公开(公告)号：EP2026768B1

公开(公告)日：2018-02-28

申请号：EP07736412.3

申请日：2007-06-03

申请人： Dexcel Pharma Technologies Ltd.

发明人： PENHASI, Adel ,  MOSES-HELLER, Sheera ,  GOMBERG, Mila ,  AVRAMOFF, Avi

IPC分类号： A61K9/20 ,  A61K9/50 ,  A61K31/4439

CPC分类号： A61K9/2886 ,  A61K9/2077 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/4439

摘要： An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer.